Barclays raised the firm’s price target on Syndax (SNDX) to $35 from $22 and keeps an Overweight rating on the shares. The firm updated the company’s model after speaking with management.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax price target lowered to $33 from $40 at JPMorgan
- Syndax Pharmaceuticals: Q3 Earnings Call Highlights
- Syndax price target raised to $38 from $35 at UBS
- Strong Growth Potential and Market Expansion Justify Buy Rating for Syndax Pharmaceuticals
- Syndax Pharmaceuticals: Strategic Advancements and Growth Potential Reinforce Buy Rating